Abstract
Effects of sofosbuvir-based therapy on the metabolic status of patients with chronic hepatitis C infection
Highlights
Hepatitis C virus (HCV) infection is a common infectious disease, affecting 71 million people worldwide
The findings showed that the mean total cholesterol level was 150.9±34.9 and 168.0±40 mg/dL before and after treatment, respectively (P=0.001)
According to the results, it can be concluded that sofosbuvir-based therapy has effects on some metabolic parameters of chronic hepatitis C virus (HCV) patients
Summary
Hepatitis C virus (HCV) infection is a common infectious disease, affecting 71 million people worldwide. Evidence shows that HCV has infected around 1.6% of the world population [3]. In Iran, the seroprevalence of HCV infection varies considerably in different provinces, ranging from 0.08% to 1.6% [4]. The prevalence of HCV antibody is estimated at 0.5% in the general population of Iran, and HCV genotype 1 is recognized as the most common circulating genotype in the country [5,6]. Treatment of HCV infection has significantly changed in recent years. Sofosbuvir is generally an HCV NS5B polymerase inhibitor and a nucleotide analog active against all HCV genotypes. In this study, we aimed to determine the effects of sofosbuvir-based therapy on the metabolic status of patients with chronic hepatitis C virus (HCV) infection
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call